-
GSK Bags Tesaro For $5B As It Leaps Back Into Commercial Oncology, Beefs Up Cancer Drug Pipeline
Endpoints News | GlaxoSmithKline has struck a deal to buy Tesaro in a $5.1 billion deal that will vault the pharma giant into the commercial oncology market as it stakes out a big new role for itself in the booming cancer field.
Dec 5, 2018
-
OmniTier Debuts CompStor Novos Platform For De Novo Assembly-Based Variant Calling
Bio-IT World News Brief | OmniTier has debuted the CompStor Novos platform for de novo assembly-based variant calling in whole genome sequencing applications.
Dec 5, 2018
-
Despite CRISPR Baby Controversy, Harvard University Will Begin Gene-Editing Sperm
MIT Technology Review | Even as a furious debate broke out in China over gene-edited babies, some scientists in the US are also hoping to improve tomorrow's children.
Nov 30, 2018
-
Facing Backlash, Chinese Scientist Defends Gene-Editing Research On Babies
NPR.org | He Jiankui, who shocked the world by asserting he had genetically edited twin girls, faced growing criticism from other researchers as he spoke at a scientific conference in Hong Kong.
Nov 28, 2018
-
UberCloud, The Wellcome Sanger Institute, Panasas, And More: News From November 2018
Bio-IT World | November featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including UberCloud, the Wellcome Sanger Institute, Panasas, and more.
Nov 28, 2018
